In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as Chi Sheng Pharma & Biotech has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
TPEX:4111 - Analysts future estimates and past financials data (TWD Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
3/31/2026
1,414
179
170
237
N/A
12/31/2025
1,376
164
180
275
N/A
9/30/2025
1,361
165
147
245
N/A
6/30/2025
1,303
140
41
146
N/A
3/31/2025
1,218
126
127
237
N/A
12/31/2024
1,165
111
128
213
N/A
9/30/2024
1,104
71
83
175
N/A
6/30/2024
1,082
73
24
132
N/A
3/31/2024
1,065
73
-67
47
N/A
12/31/2023
1,061
69
-27
75
N/A
9/30/2023
1,090
116
9
111
N/A
6/30/2023
1,115
151
89
197
N/A
3/31/2023
1,130
164
107
225
N/A
12/31/2022
1,143
179
109
215
N/A
9/30/2022
1,105
186
128
216
N/A
6/30/2022
1,085
150
-73
197
N/A
3/31/2022
1,059
129
-100
164
N/A
12/31/2021
1,022
108
-126
139
N/A
9/30/2021
1,003
56
-137
125
N/A
6/30/2021
971
41
61
103
N/A
3/31/2021
953
46
87
109
N/A
12/31/2020
979
59
121
144
N/A
9/30/2020
1,005
72
101
129
N/A
6/30/2020
1,026
80
152
177
N/A
3/31/2020
1,047
85
179
206
N/A
12/31/2019
1,023
72
N/A
163
N/A
9/30/2019
998
57
N/A
187
N/A
6/30/2019
985
57
N/A
134
N/A
3/31/2019
964
46
N/A
87
N/A
12/31/2018
967
42
N/A
114
N/A
9/30/2018
985
52
N/A
98
N/A
6/30/2018
1,016
60
N/A
133
N/A
3/31/2018
1,032
69
N/A
157
N/A
12/31/2017
1,045
82
N/A
181
N/A
9/30/2017
1,034
91
N/A
162
N/A
6/30/2017
1,012
88
N/A
160
N/A
3/31/2017
995
85
N/A
133
N/A
12/31/2016
964
73
N/A
104
N/A
9/30/2016
946
48
N/A
130
N/A
6/30/2016
936
46
N/A
120
N/A
3/31/2016
938
42
N/A
116
N/A
12/31/2015
932
39
N/A
97
N/A
9/30/2015
908
40
N/A
92
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 4111's forecast earnings growth is above the savings rate (1.3%).
Earnings vs Market: Insufficient data to determine if 4111's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 4111's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 4111's revenue is forecast to grow faster than the TW market.
High Growth Revenue: Insufficient data to determine if 4111's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4111's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/03 20:57
End of Day Share Price
2026/08/03 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chi Sheng Pharma & Biotech Co., Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.